Compositions and methods for treating neurological disorders and diseases
First Claim
Patent Images
1. A method of selecting agents that are potentially useful for the treatment of Alzheimer'"'"'s disease, comprising the steps of:
- contacting focal adhesion kinase 2 with a test agent;
measuring a biological activity related to focal adhesion kinase 2 function in the presence and absence of said test agent; and
comparing the difference in the measured biological activity in the presence and absence of said test agent, wherein a difference indicates the test agent is potentially useful for the treatment of Alzheimer'"'"'s disease.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention generally relates to methods and compositions for treating neurological disorders and diseases. In addition, methods for selecting therapeutic agents useful for treating neurological disorders and diseases are provided.
-
Citations
19 Claims
-
1. A method of selecting agents that are potentially useful for the treatment of Alzheimer'"'"'s disease, comprising the steps of:
-
contacting focal adhesion kinase 2 with a test agent;
measuring a biological activity related to focal adhesion kinase 2 function in the presence and absence of said test agent; and
comparing the difference in the measured biological activity in the presence and absence of said test agent, wherein a difference indicates the test agent is potentially useful for the treatment of Alzheimer'"'"'s disease. - View Dependent Claims (2, 3, 4, 5)
-
- 6. A method of treating or delaying the onset of Alzheimer'"'"'s disease in an individual in need of such treatment, comprising inhibiting focal adhesion kinase 2 in said individual by administering to said individual an inhibitor of focal adhesion kinase 2.
-
11. A method of reducing Aβ
-
42 in an individual in need of such treatment, comprising inhibiting focal adhesion kinase 2 in said individual by administering to the individual an Aβ
42-reducing effective amount of an inhibitor of focal adhesion kinase 2. - View Dependent Claims (12, 13, 14, 15)
-
42 in an individual in need of such treatment, comprising inhibiting focal adhesion kinase 2 in said individual by administering to the individual an Aβ
- 16. A method of diagnosis or prognosis of Alzheimer'"'"'s disease in an individual, comprising determining the level or activity of focal adhesion kinase 2 in said individual.
-
18. An isolated protein complex comprising a first protein interacting with a second protein, wherein said first protein is (1) focal adhesion kinase 2;
- (2) a focal adhesion kinase 2 fragment;
(3) a fusion protein comprising (1) or (2);
or (4) a focal adhesion kinase 2 homologue having an amino acid sequence at least 75% identical to (1) or (2); and
wherein second protein is selected from the group consisting of focal adhesion kinase 2, ATP-binding cassette transporter, sub-family C, member 8, and delta-catenin, and fragments, and homologues thereof, and fusion protein thereof. - View Dependent Claims (19)
- (2) a focal adhesion kinase 2 fragment;
Specification